Harrison Robert Gardner, serving as Chief Information Officer at Sera Prognostics (NASDAQ:SERA), completed the sale of 2,000 shares of the companys Class A common stock on January 27, 2026. The disposition was transacted at a weighted average price of $2.97 per share, producing total proceeds of $5,940. Reported sale prices ranged from $2.92 to $3.06.
Following this sale, Gardner retains direct ownership of 82,788 shares of Sera Prognosticss stock. The transaction was carried out under a Rule 10b5-1 trading plan that was adopted on May 21, 2025, according to the filing details.
Those insider activity details arrive alongside the companys recently released Q3 2025 financials, which presented a mixed picture. Sera posted earnings per share of -$0.16, a figure that was better than the analyst consensus of -$0.23 and therefore represented a positive surprise of 30.43 percent. Revenue for the quarter, however, registered at $16,000, substantially below the expected $150,000 and constituting an 89.33 percent negative surprise versus forecasts.
In addition to the financials, Sera announced positive results from a large clinical trial of its PreTRM Test, a blood-based predictive biomarker assay designed to identify pregnant women at higher risk for spontaneous preterm birth. The trial enrolled 5,018 women and reported that the use of the blood test, when coupled with targeted interventions, reduced rates of very early and early preterm births. The published study in the journal PREGNANCY documented a 56 percent reduction in births before 32 weeks and a 32 percent reduction in births before 35 weeks.
Market coverage developments include Jefferies initiating coverage on Sera Prognostics with a Buy rating and a $5.00 price target, noting the companys emphasis on predictive biomarker testing for pregnancy complications. These items - insider selling under a pre-established plan, a mixed earnings release with a negative EPS that beat estimates, a significant revenue shortfall, positive clinical trial findings, and new analyst coverage - form the factual context around Sera at this time.
Summary of facts
- Insider sale: 2,000 shares sold by CIO Harrison Robert Gardner on January 27, 2026 at a weighted average price of $2.97.
- Post-sale ownership: Gardner directly owns 82,788 shares.
- Trading plan: Sale executed under a Rule 10b5-1 plan adopted May 21, 2025.
- Q3 2025 results: EPS of -$0.16 versus -$0.23 expected; revenue $16,000 versus $150,000 expected.
- Clinical trial: PreTRM Test trial of 5,018 women showing a 56 percent reduction in births before 32 weeks and 32 percent reduction before 35 weeks, published in PREGNANCY.
- Analyst action: Jefferies initiates coverage with a Buy rating and $5.00 target.